CRD-100 is under clinical development by Curadev Pharma and currently in Phase I for Bone Sarcoma. According to GlobalData, Phase I drugs for Bone Sarcoma have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CRD-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CRD-100 overview

CRD-100 is under development for the treatment of sarcomas like undifferentiated pleomorphic sarcoma or myxofibrosarcoma, angiosarcoma, bone sarcoma or merkel cell carcinoma. The drug candidate is a small molecule that act by targeting STING adaptor protein. It is administered through intravenous route.

Curadev Pharma overview

Curadev Pharma (Curadev) discovers and develops small molecule drug candidates to treat cancers and hematological disorders. Its immuno-oncology research programs include stimulator of interferon genes (STING) agonist and antagonist, antibody drug conjugate and small molecule inhibitors for treating liquid and solid tumors and inflammation disorders. The company developed potent small molecules inhibitors that reduce kynurenine levels in experimental paradigms. Curadev conducts research in the areas of immune oncology, metabolism, lymphoma treatment and autoimmune diseases. The company works in collaboration with University of Texas Southwestern Medical Centre, INSERM, All India Institute of Medical Sciences and Indian Institute of Technology to advance the development of its pipeline products. Curadev is headquartered in Noida, Uttar Pradesh, India.

For a complete picture of CRD-100’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.